Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS.<ref name=cilanserton>[http://www.drugdevelopment-technology.com/projects/cilanserton/ General info on Cilansetron]</ref> Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.<ref name=cilanserton/>
Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS.<ref name=cilanserton>[http://www.drugdevelopment-technology.com/projects/cilanserton/ General info on Cilansetron]</ref> Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.<ref name=cilanserton/>
In 2005, Solvay received response from the U.S. Food and Drug Administration that cilanserton is not approvable without additional clinical trials;<ref>{{cite news | url = http://www.pharmatimes.com/news/solvays_cilansetron_not_approvable_998463 | title = Solvay's cilansetron “notapprovable” | date = April 4, 2005 | publisher = PharmaTimes | access-date = August 14, 2019}}</ref><ref>{{cite web | url = https://www.drugs.com/history/calmactin.html | title = Calmactin Approval Status | access-date = August 14, 2019 | publisher = [[Drugs.com]] }}</ref> further development has been discontinued.<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800005297 | title = Cilansetron | access-date = August 14, 2019}}</ref>
In 2005, Solvay received response from the U.S. Food and Drug Administration that cilanserton is not approvable without additional clinical trials;<ref>{{cite news | url = http://www.pharmatimes.com/news/solvays_cilansetron_not_approvable_998463 | title = Solvay's cilansetron "not approvable" | date = April 4, 2005 | publisher = PharmaTimes | access-date = August 14, 2019}}</ref><ref>{{cite web | url = https://www.drugs.com/history/calmactin.html | title = Calmactin Approval Status | access-date = August 14, 2019 | publisher = [[Drugs.com]] }}</ref> further development has been discontinued.<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800005297 | title = Cilansetron | access-date = August 14, 2019}}</ref>
5-HT3 receptors are responsible for causing many things from nausea to excess bowel movements. In conditions such as irritable bowel syndrome (IBS), the receptors have become faulty or oversensitive. 5-HT3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.
Studies have shown that the drug can improve quality of life in men and women with diarrhea-predominant IBS.[1] Cilansetron is the first 5-HT antagonist specifically designed for IBS that is effective in men as well as women.[1]
In 2005, Solvay received response from the U.S. Food and Drug Administration that cilanserton is not approvable without additional clinical trials;[2][3] further development has been discontinued.[4]
